Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07117487) titled 'A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants =60 Years of Age' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).
Primary Sponsor: ModernaTX, Inc.
Condition:
Respiratory Syncytial Virus
Intervention:
Biological: mRNA-1345
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: August 5, 2025
Target Sample Size: 500
Countries of Recruitment:
United States
To know more, visit ...